Research on inflammation and peptides shows that reducing visceral fat decreases systemic inflammatory signals, creating a positive feedback loop where lower inflammation further supports metabolic improvements
Topline histology results from ENLIGHTEN-Fibrosis are anticipated in the first half of 2027, followed by results from ENLIGHTEN-Cirrhosis in 2028
A GLP-1 to TRT or HRT cross-sell adds roughly 3 to 5x the LTV of a single-program patient
Every TRT Nation tirzepatide prescription includes it as a standard part of the formulation
A third study, about the drugs effect on glaucoma, is on the horizon
GLP-1RA has gained a sudden surge in popularity for its ability to trigger glycemic control, weight loss, and cardiovascular risk reduction [Reference Baggio and Drucker3Reference Taha, Yahya, Satish, Laird, Agatston and Cainzos-Achirica6]